Current Hematologic Malignancy Reports

Papers
(The H4-Index of Current Hematologic Malignancy Reports is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
CAR-T Cell Therapy: the Efficacy and Toxicity Balance38
IDH Inhibitors in AML—Promise and Pitfalls38
MRD Assessment in Multiple Myeloma: Progress and Challenges34
Balancing Quality, Cost, and Access During Delivery of Newer Cellular and Immunotherapy Treatments31
Enteropathy-Associated T cell Lymphoma20
Treatment-Free Remission: the New Goal in CML Therapy19
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies18
Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders17
Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia16
Novel Pathophysiological Mechanisms of Thrombosis in Myeloproliferative Neoplasms15
Molecular Pathogenesis of Myeloproliferative Neoplasms15
Differential Diagnosis and Workup of Monocytosis: A Systematic Approach to a Common Hematologic Finding14
Tweeting from the Bench: Twitter and the Physician-Scientist Benefits and Challenges14
Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms14
0.031702041625977